CGC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Canopy Growth Corp (CGC) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with declining revenue, net income, and EPS. Additionally, the stock has been underperforming, and there are no strong technical or trading signals to suggest a near-term recovery. While there are some positive catalysts, such as the MTL Cannabis acquisition, the overall risks outweigh the potential benefits for a beginner investor.
The MACD is slightly positive but contracting, suggesting limited momentum. RSI is neutral at 49.04, indicating no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key support is at 1.048, and resistance is at 1.201. Overall, the technical indicators do not provide a strong buy signal.
The acquisition of MTL Cannabis, which is profitable and cash flow positive, received strong shareholder approval and could strengthen Canopy Growth's position in the Canadian medical cannabis market. Regulatory changes may provide expansion opportunities in the U.S.
The stock has dropped over 95% since its IPO, reflecting ongoing financial struggles. Recent financials show significant declines in revenue, net income, and EPS. The company recapitalized its balance sheet, signaling financial weakness, and the MTL Cannabis acquisition will dilute existing shareholders. Cannabis stocks, including Canopy Growth, have underperformed over the past five years.
In Q3 2026, revenue dropped to $74.54 million (-0.29% YoY), net income dropped to -$62.63 million (-48.62% YoY), EPS dropped to -0.18 (-83.78% YoY), and gross margin dropped to 28.8% (-10.64% YoY). These metrics highlight significant financial deterioration.
Alliance Global recently lowered the price target from C$2.50 to C$1.80, maintaining a Neutral rating. Analysts have expressed concerns about gross margins and the impact of changes to veteran reimbursement. Previous optimism about the MTL Cannabis acquisition has been overshadowed by ongoing financial struggles.
